Skip to Navigation
London School of Hygiene & Tropical Medicine Malaria Centre

American Society of Tropical Medicine & Hygiene Meeting 2014: malaria highlights

 
Image: Bill Gates at ASTMH meeting 2014. Photograph courtesy of Getty Images
 

Image: Bill Gates at ASTMH meeting 2014. Photograph courtesy of Getty Images

09 November 2014
Bill Gates' announcement to increase malaria funding, strategic plans from the WHO to eliminate malaria and ACT Consortium research results were some of the malaria contributions seen at this year's meeting

View the original story on the ACT Consortium web site.

During the opening speech in New Orleans, Bill Gates addressed the Ebola crisis, but devoted the bulk of his time to another killer disease: malaria. The Bill & Melinda Gates Foundation will increase its malaria programme budget by 30 percent, to more than $200 million per year.

Dr Anja Terlouw presented reassuring preliminary results from the ACTia trial in Malawi. Early analysis of study data do not show that repeated ACT treatment is unsafe for young children.

Katia Bruxvoort's research showed that in both the public and retail sectors in Tanzania patient adherence to ACT treatment was sub-optimal.

Dr Harparkash Kaur presented reassuring results from a large-scale drug quality analysis of over 10,000 ACT samples across several countries in Africa.

Dr Pedro L. Alonso, the new Director of the Global Malaria Programme, introduced the context and need for a new Global Technical Strategy (GTS) for malaria. Between 2016 and 2030, the strategy aims to ensure universal access to malaria prevention diagnosis and treatment, accelerate efforts towards elimination and attainment of malaria free status, as well as to transform malaria surveillance into a core intervention.

Dr Alonso also highlighted that country ownership and the participation of communities are essential to reach the elimination targets (35 countries by 2030).

David Brandling-Bennett, Senior Malaria Advisor for the Bill & Melinda Gates Foundation and a member of the ACT Consortium Expert Oversight Committee, encouraged the malaria community to provide input into Roll Back Malaria's second Global Malaria Action Plan (GMAP2).

To date, more than 1100 stakeholders have been consulted directly, and more than 100 completed the online survey.

ACT Consortium statistician Baptiste Leurent presented research on whether the use of exit interviews at health facilities can influence how health workers adhere to guidelines.

Cheryl Pace presented a novel data collection tool to facilitate the capture of harms data. She encouraged the research community to use the Safety Adverse Event forms to assess general, non malaria-specific safety issues.

The presentation highlighted the overlap between the adverse events reported by both field workers and clinicians, and the consequent need to train both groups in adverse event monitoring.

D├ębora Miranda presented a communications toolkit to maximise research impact, based on experience from the ACT Consortium.

Dr Hugh Reyburn, Dr Heidi Hopkins and Dr John Crump led a symposium on Non-Malaria Febrile Illness (NFMI). An early version of a novel NMFI web mapping tool was presented and the research community is welcome to provide feedback.

Baptiste Leurent presented the impact of malaria rapid diagnostic tests (RDTs) on care of febrile patients, based on results from various ACT Consortium studies.

Prof David Schellenberg, the director of the ACT Consortium led a Monitoring & Evaluation symposium. Dr Anja Terlouw presented a rolling malaria indicator survey developed in Malawi which tracks malaria hotspots at a sub-district level.

Symposium speakers highlighted the need to target malaria control efforts at a local level, improve the management of surveillance systems and maintain capacity building to help those systems.

*Presentations will be available soon

Further information